Food Derived Compounds Block Prostate Cancer Growth

Specific natural food compounds may inhibit the growth of prostate cancer, a new study suggests.
For the past decade, cancer research has pointed towards the potential use of compounds derived from plants and foods, including apple peels, green tea, and turmeric. These compounds help minimize inflammation in the body, a risk factor for cancer.
In a study published in Precision Oncology, investigators tested 142 natural compounds on mouse and human cell lines to determine which compounds could inhibit prostate cancer cell growth when used alone or in combination with other nutrients.
“After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,” said corresponding author Stefano Tiziani. “The beauty of this study is that we were able to inhibit tumor growth in mice without toxicity.”
The investigators identified ursolic acid, a natural chemical found in apple peels and rosemary; curcumin, a compound in turmeric; and resveratrol, a natural compound in red grapes or berries, as the most promising active ingredients and tested them on animal models.
“These nutrients have potential anti-cancer properties and are readily available,” Tiziani said. “We only need to increase concentration beyond levels found in a healthy diet for an effect on prostate cancer cells.”
The study also showed that combining ursolic acid with either curcumin or resveratrol can prevent cancer cells from accessing crucial nutrients needed to survive. In other words, through nutrients commonly found in the human diet, the compounds can block the uptake of glutamine, which prostate cancer cells need to grow.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

The supplemental New Drug Application supports the expansion of niraparib’s indication as a late-line therapeutic option for patients with ovarian cancer.
Compared with nontargeted therapy, targeted therapies demonstrated a survival advantage for patients 65 years and older with metastatic renal cell carcinoma.
Patients with multiple sclerosis who switched disease-modifying treatments at least twice had a higher relative risk of developing cancer.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.